Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong

BACKGROUND: Pembrolizumab, a monoclonal antibody against programmed death ligand 1 (PD-L1), is approved by several regulatory agencies for first-line treatment of metastatic non-small-cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) ≥ 50% and no epidermal growth factor receptor (EG...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmacoecon Open
Main Authors: Loong, Herbert H., Wong, Carlos K. H., Leung, Linda Kam Suet, Dhankhar, Praveen, Insinga, Ralph P., Chandwani, Sheenu, Hsu, Danny C., Lee, Mary Y. K., Huang, Min, Pellissier, James, Rai, Akanksha, Achra, Monika, Tan, Seng Chuen
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2019
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7248157/
https://ncbi.nlm.nih.gov/pubmed/31531842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-019-00178-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados